FOXC2 and prostate carcinoma: In conclusion, unravelling the expression levels of FOXC2 and the presence of epithelial–mesenchymal phenotypes in various settings of prostate cancer, and the relation to long term outcome, may have important implications for future prognostication, stratification and targeted therapy of prostate cancer patients.